Evidence map›Paper›PMID 38166725›Full record

ArticleBMC pulmonary medicine2024

Vitamin D3 improved hypoxia-induced lung injury by inhibiting the complement and coagulation cascade and autophagy pathway.

Chongyang Dai, Xue Lin, Yinglian Qi, Yaxuan Wang, Zhongkui Lv, Fubang Zhao, Zhangchang Deng, Xiaokai Feng, Tongzuo Zhang, Xiaoyan Pu

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Chongyang Dai *Qinghai University, Xining, Qinghai Province, 810016, People's Republic of China.
Xue Lin *West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610000, People's Republic of China.
Yinglian QiQinghai Normal University, Xining, Qinghai Province, 810008, People's Republic of China.
Yaxuan WangQinghai University, Xining, Qinghai Province, 810016, People's Republic of China.
Zhongkui LvQinghai University, Xining, Qinghai Province, 810016, People's Republic of China.
Fubang ZhaoQinghai University, Xining, Qinghai Province, 810016, People's Republic of China.
Zhangchang DengQinghai University, Xining, Qinghai Province, 810016, People's Republic of China.
Xiaokai FengDepartment of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China. fengxiaokai2020@163.com.
Tongzuo ZhangNorthwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, Qinghai Province, 810001, People's Republic of China. zhangtz@nwipb.cas.cn.
Xiaoyan PuQinghai University, Xining, Qinghai Province, 810016, People's Republic of China. puxiaoyan1975@163.com.
Qinghai University · CNBeijing Chao-Yang Hospital · CNChinese Academy of Sciences · CNQinghai Normal University · CNWest China Hospital of Sichuan University · CN

Funding

the Chinese National Natural Science Foundation 82160322the Department of Science and Technology of Qinghai Province 2023-ZJ-746
6 · The paper itself

Abstract

backgroundPulmonary metabolic dysfunction can cause lung tissue injury. There is still no ideal drug to protect against hypoxia-induced lung injury, therefore, the development of new drugs to prevent and treat hypoxia-induced lung injury is urgently needed. We aimed to explore the ameliorative effects and molecular mechanisms of vitamin D3 (VD3) on hypoxia-induced lung tissue injury.

methodsSprague-Dawley (SD) rats were randomly divided into three groups: normoxia, hypoxia, and hypoxia + VD3. The rat model of hypoxia was established by placing the rats in a hypobaric chamber. The degree of lung injury was determined using hematoxylin and eosin (H&E) staining, lung water content, and lung permeability index. Transcriptome data were subjected to differential gene expression and pathway analyses. In vitro, type II alveolar epithelial cells were co-cultured with hepatocytes and then exposed to hypoxic conditions for 24 h. For VD3 treatment, the cells were treated with low and high concentrations of VD3.

resultsTranscriptome and KEGG analyses revealed that VD3 affects the complement and coagulation cascade pathways in hypoxia-induced rats, and the genes enriched in this pathway were Fgb/Fga/LOC100910418. Hypoxia can cause increases in lung edema, inflammation, and lung permeability disruption, which are attenuated by VD3 treatment. VD3 weakened the complement and coagulation cascade in the lung and liver of hypoxia-induced rats, characterized by lower expression of fibrinogen alpha chain (Fga), fibrinogen beta chain (Fgb), protease-activated receptor 1 (PAR1), protease-activated receptor 3 (PAR3), protease-activated receptor 4 (PAR4), complement (C) 3, C3a, and C5. In addition, VD3 improved hypoxic-induced type II alveolar epithelial cell damage and inflammation by inhibiting the complement and coagulation cascades. Furthermore, VD3 inhibited hypoxia-induced autophagy in vivo and in vitro, which was abolished by the mitophagy inducer, carbonyl cyanide-m-chlorophenylhydrazone (CCCP).

conclusionVD3 alleviated hypoxia-induced pulmonary edema by inhibiting the complement and coagulation cascades and autophagy pathways.

Indexed as

Lung InjuryPulmonary EdemaAnimalsAutophagyCholecalciferolFibrinogenHypoxiaInflammationRatsRats, Sprague-DawleyCholecalciferolFibrinogenAutophagyComplement and coagulation cascadeHypoxia-induced lung injuryVitamin D3

Identifiers

PMID38166725
PMCPMC10759436
OpenAlexW4390507690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.